QualityStocks would like to highlight BSD Medical Corporation (NASDAQ: BSDM). The company develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD's product lines include both hyperthermia and ablation treatment systems. BSD's hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD's microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue.
In the company’s news yesterday,
BSD Medical recently announced that its BSD-2000 Hyperthermia System has been purchased by the prestigious University of California San Francisco Medical Center. The system will now be available as a treatment option for the center’s patients.
One of the top 10 hospitals in the U.S., UCSF Medical Center is recognized around the world for its advanced patient care and cutting-edge technology. The center is one of the leading cancer care providers in the world. UCSF Medical Center’s Comprehensive Cancer Center was awarded the prestigious “comprehensive” designation from the National Cancer Institute and ranks sixth in the nation in NCI research grants. UCSF Medical Center employs more than 7,000 people at its numerous facilities.
UCSF has a longstanding history of providing cutting-edge therapies to patients. The center also recently purchased a BSD-500 Hyperthermia System from BSD Medical Corporation, and the company is pleased they will also be offering the BSD-2000’s pioneering capabilities to their patients.
The BSD-2000, which has been exclusively developed and patented by BSD, provides localized therapeutic heating (hyperthermia) through the application of radiofrequency (RF) energy. The system creates a central focus of energy that is capable of electronically focusing to target the shape, size, and location of a tumor, thereby providing dynamic control of the heating delivered to the tumor region. The system has Humanitarian Device Exemption (HDE) marketing approval from the FDA for use in conjunction with radiation therapy to treat cervical cancer patients who are not eligible for chemotherapy. Additionally, the BSD-2000 has CE Marking approval for commercial sale in Europe and many countries outside of the European Union.
BSD Medical Corporation is engaged in the development, manufacturing, marketing, and servicing of systems for the treatment of cancer and benign diseases by means of heat therapy delivered via RF and microwave energy. The company’s product lines include systems for treating both hyperthermia and ablation.
In use for several years in the U.S., Europe, and Asia, BSD’s hyperthermia cancer treatment systems are used for treating certain tumors with heat (hyperthermia) while simultaneously increasing the effectiveness of other therapies like radiation therapy. The company’s microwave ablation system has been developed as a standalone therapy for employing precision-guided microwave energy to destroy soft tissue.
BSD has developed substantial intellectual property and multiple products in the market, and the company has established distribution in the U.S., Europe, and Asia. Some of the company’s products have been granted regulatory approvals and clearances in the U.S., Europe, and China.
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.